Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia
Completed
The purpose of this study is to evaluate clinical and laboratory safety associated with the administration of GVAX leukemia vaccine and to determine the feasibility of generation of GVAX leukemia vaccine in subjects with acute myelogenous leukemia (AML).
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
12/18/2007
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Acute Myelogenous Leukemia